Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

2seventy bio, Inc. - Common Stock (NQ: TSVT )

3.960 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Expert Ratings for 2seventy bio
Via Benzinga
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
4 Analysts Have This to Say About 2seventy bio
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
Via Benzinga
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
The Top E-Commerce Company to Buy for Summer 2022
There's definitely a chance that struggling RealReal simply goes bankrupt, but its network effects could make it a buyout target. 
Via InvestorPlace
The 5 Top Profit & Protection Stocks to Buy for 2022
It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success. 
Via InvestorPlace
2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
Upgrades 
Via Benzinga
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Secures $170 Million in Private Placement Equity Financing
From 2seventy bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.